Date: 2015-06-17
Type of information: R&D agreement
Compound: undisclosed early-stage Lilly oncology compounds
Company: Eli Lilly (USA - IN) Dana-Farber Cancer Institute (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On June 17, 2015, Eli Lilly and Dana-Farber Cancer Institute announced a multiyear collaboration to research new medicines under development to fight cancer. Per the agreement, over the course of three years Dana-Farber will provide research and development expertise for a number of early-stage Lilly oncology compounds. Dana-Farber researchers and Lilly scientists will work collaboratively on preclinical and clinical studies, molecular studies of patient samples and the design and conduct of clinical trials, which may result in important advances in the science of cancer care. The agreement also allows Dana-Farber scientists to conduct independent studies on select Lilly compounds. Following research conducted at Dana-Farber, the evaluated compounds will still be fully owned by Lilly.
Financial terms: Financial terms of the agreement are not being disclosed.
Latest news:
